Last updated: February 17, 2026
What Is NDC 10631-0007?
NDC 10631-0007 refers to a specific drug product, identified by the National Drug Code (NDC). This code corresponds to Imetelstat, a telomerase inhibitor under development primarily for hematologic malignancies such as myelofibrosis and other indications.
While the precise product details (manufacturer, formulation, strength) under this code are confidential, ongoing clinical trials and regulatory submissions indicate its positioning in the hematology-oncology space.
Market Size and Dynamics
Current Market Size
- The global hematology-oncology drug market was valued at approximately USD 22 billion in 2022.
- The market for telomerase inhibitors remains niche, with fewer players and a focus on rare or underserved indications.
- Imetelstat's targeted indications (e.g., myelofibrosis) have a rare disease classification, limiting total addressable market (TAM).
Key Competitors
- The primary competitor in hematologic telomerase inhibition is GRN510 (Genentech), though clinical progress varies.
- Existing treatments include JAK inhibitors like ruxolitinib (Incyte), which has a broader indication but lower disease specificity.
- Imetelstat’s potential market depends on FDA approval, which hinges on clinical trial outcomes.
Market Drivers
- Unmet needs in myelofibrosis and other myelodysplastic syndromes.
- Increasing number of clinical trials with positive results.
- Potential for expanding indications to other hematologic malignancies.
Regulatory Environment
- Fast-track designation granted by FDA for several hematological indications.
- Priority review process in development stages.
- Pending NDA submission expected in the next 12-24 months.
Price Projections
Current Pricing Landscape
- Currently, no approved pricing for NDC 10631-0007, as it remains investigational.
- Approved therapies for myelofibrosis (e.g., Jakafi) have wholesale prices averaging USD 60,000–USD 80,000 annually per patient.
Projected Launch and Pricing Assumptions
- If approved, Imetelstat might price similarly or at a premium, given its targeted mechanism and potential superiority.
- Price sensitivity depends on clinical efficacy, safety profile, and market competition.
| Scenario |
Estimated Annual Price Per Patient |
Key Assumptions |
| Conservative (entry-level) |
USD 60,000 |
Comparable to existing therapies, minor premium |
| Moderate (mid-tier upgrade) |
USD 80,000 |
Efficacy benefits, improved safety profile |
| Premium (breakthrough) |
USD 100,000+ |
Significant clinical advantage, limited competition |
Market Penetration and Revenue Projections
- Assuming launch in Year 3 of the forecast period.
- Initial adoption rate: 10-15% of eligible patients.
- Market penetration grows as more data confirms benefits and indications expand.
| Year |
Patient Eligible (Estimated) |
Market Penetration Rate |
Approximate Revenue (USD) |
| 2024 |
2,000 |
0% (pre-launch) |
USD 0 |
| 2025 |
2,000 |
10% |
USD 12 million |
| 2026 |
2,200 |
20% |
USD 35 million |
| 2027 |
2,200 |
30% |
USD 50 million |
Note: These projections assume favorable clinical outcomes and regulatory approval.
Pricing Risks and Market Challenges
- Pricing pressures from payers due to cost containment policies.
- Competition from existing JAK inhibitors and emerging therapies.
- Market penetration depends heavily on clinical trial success and approval timeline.
Key Takeaways
- NDC 10631-0007 (Imetelstat) operates within a niche hematological market with limited competition but high unmet needs.
- The US market potential ranges between USD 60 million and USD 150 million annually within five years of launch, depending on clinical success.
- Pricing likely mirrors existing hematology-oncology drugs unless significant efficacy advantages justify premium pricing.
- Market entry timing, regulatory approvals, and clinical trial results are critical variables influencing revenues.
- Expanding indications could substantially increase the addressable market over time.
FAQs
1. When could NDC 10631-0007 potentially reach the market?
Regulatory filings are expected in the next 12-24 months, with potential approval and launch around 2024-2025.
2. How does Imetelstat compare to existing treatments?
It targets telomerase specifically, which may offer different efficacy and safety profiles than JAK inhibitors like ruxolitinib.
3. What factors influence pricing strategies for this drug?
Clinical efficacy, safety data, market competition, and payer reimbursement policies primarily shape pricing.
4. How large is the patient population for conditions targeted by Imetelstat?
Myelofibrosis affects approximately 2-3 per 100,000 adults globally, translating to a few thousand eligible patients in the US.
5. What are the primary risks to market success?
Failure to secure regulatory approval, unfavorable clinical trial outcomes, or rapid emergence of competitors.
Sources
- EvaluatePharma, "Global Hematology-Oncology Market Report 2022."
- FDA, "Fast Track Designation and Priority Review," 2022.
- Pharmaceutical Data, "Pricing Trends for Hematologic Malignancies," 2022.
- American Cancer Society, "Myelofibrosis Statistics," 2022.
- ClinicalTrials.gov, "Imetelstat Clinical Trials," 2022.
